Hematology-Oncology
Mitapivat in Sickle Cell Disease: A Promising Oral Therapy to Improve Hemolytic Anemia and Reduce Complications
The phase 3 RISE UP trial demonstrates that mitapivat significantly improves hemoglobin levels in sickle cell disease, offering a novel, well-tolerated oral treatment with potential to modify disease outcomes.
